52North is a Cambridge, UK-based med-tech company developing low-cost products to streamline urgent care pathways in oncology and improve patient safety across socio-economic groups. Its flagship product, Neutrocheck®, was granted breakthrough status by the UK Government under the Innovative Devices Access Pathway earlier this year. The company's products are still in development, have not been authorised by regulators and are not currently available for sale. 52North plans to use the £4.72M in newly raised funding to advance its products toward market. Founded in 2018 by University of Cambridge postgraduates, the company focuses on urgent care pathways in oncology. 52North, founded in 2018 and based in Cambridge, develops Neutrocheck, a portable device plus app that enables cancer patients to test their risk of life-threatening neutropenic sepsis at home or in clinical settings. The company’s mission is to improve health outcomes and health equity by reinventing care pathways. 52North was named Medtech Company of the Year at the 2023 Cambridge Independent Science & Technology Awards. It has joined two major US accelerator programmes — Cedars‑Sinai and Texas Medical Centre — and is participating in a US incubator to drive international expansion. Participation in those programmes, funded in part by Innovate UK’s Global Business Incubator programme, has included over 50 mentor interactions with clinicians and insurers to refine the US value proposition. The company has engaged in industry events and collaborations, including presentations at HLTH and the Texas Life Sciences Forum and a new collaboration with Cedars‑Sinai’s Tatonetti Lab; financially it received a $100,000 investment from Cedars‑Sinai alongside other investors. Founded in 2018 and based in the UK, 52 North Health has developed NeutroCheck, a small portable device paired with a digital platform that assesses neutropenic sepsis risk from a blood finger-prick. The solution aims to triage patients at home so at-risk patients are prioritised for urgent care while low-risk patients can avoid unnecessary A&E visits. The company plans to incorporate UnifAI Technology’s AI-powered digital reader into the solution and to progress through its first clinical trial. With a new grant from Innovate UK, the startup will scale development, hit key clinical milestones and prepare for clinical validation. The clinical validation study is expected to begin next summer and involve about 250 patients, followed by an at-home test of the device for around 30 patients. Results will support a regulatory submission for UKCA and CE marking and build evidence to enable NHS roll-out. 52 North Health developed NeutroCheck, a low-cost clinical AI point-of-care device and digital platform for at-home monitoring of neutropenic sepsis risk in cancer patients. The company says NeutroCheck improves safety, quality of life and care pathways by enabling remote monitoring and AI-driven risk prediction. Its platform combines patient and clinician input with predictive models to inform treatment decisions. The startup is women-led and founded in 2018 at the GPS coordinates of Cambridge. 52 North plans to use its recent funding to advance NeutroCheck through U.K. clinical trials and to pursue strategic partnerships with organisations such as the UK Sepsis Trust and Macmillan Cancer Support. The company positions health equity and improved outcomes at the heart of its solutions.

Total raised

$9M

Funding rounds

4

Latest round

Equity

Latest activity

Dec 2024